We also explored the effect of GBPs‐score in the immunotherapy response of other cancers (including bladder cancer, gastric cancer, melanoma, and non‐small cell lung cancer) from eight immunotherapy‐related cohorts (six ICB cohorts, one adoptive T cell therapy cohort, and one MAGE‐A3 therapy cohort). This evidence concerns the gene MAGEA3 and melanoma.